beclamide
{{Short description|Chemical compound}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 413883613
| IUPAC_name = N-Benzyl-3-chloropropanamide
| image = Beclamide.svg
| image_class = skin-invert-image
| width = 190
| tradename =
| pregnancy_category =
| legal_AU =
| legal_BR = C1
| legal_BR_comment = {{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=Diário Oficial da União |language=pt-BR |publication-date=2023-04-04}}
| legal_US =
| legal_UK =
| legal_UN =
| legal_status =
| routes_of_administration = By mouth
| bioavailability =
| metabolism =
| excretion =
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 501-68-8
| ATC_prefix = N03
| ATC_suffix = AX30
| PubChem = 10391
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9962
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F5N0ALI65V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07300
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 64195
| C=10 | H=12 | Cl=1 | N=1 | O=1
| smiles = ClCCC(=O)NCc1ccccc1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JPYQFYIEOUVJDU-UHFFFAOYSA-N
| melting_point = 94
}}
Beclamide (marketed as Chloracon, Hibicon, Posedrine, Nydrane, Seclar, and other names) is a drug that possesses anticonvulsant activity.{{cite journal |vauthors=Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP |title=Metabolism of beclamide after a single oral dose in man: quantitative studies |journal=The Journal of Pharmacy and Pharmacology |volume=47 |issue=10 |pages=876–8 |date=October 1995 |pmid=8583359 |doi= 10.1111/j.2042-7158.1995.tb05757.x|s2cid=19556266 }} It is no longer used.
Uses
It has been used as a sedative and as an anticonvulsant.
It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures.
Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.{{cite journal |vauthors=Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM |title=Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide |journal=Acta Psychiatrica Scandinavica |volume=81 |issue=2 |pages=162–7 |date=February 1990 |pmid=2183543 |doi= 10.1111/j.1600-0447.1990.tb06472.x|s2cid=26772370 }}
Side effects
Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.
References
{{reflist}}
- The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). {{ISBN|0-8247-8549-5}}.
{{Anticonvulsants}}
{{anticonvulsant-stub}}